日本ケミファの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2020/08/12 | 2,421 | 2,447 | 2,393 | 2,410 | -13 | -0.5% | 5,100 |
2020/08/11 | 2,365 | 2,460 | 2,365 | 2,423 | +63 | +2.7% | 6,900 |
2020/08/07 | 2,352 | 2,389 | 2,352 | 2,360 | +8 | +0.3% | 600 |
2020/08/06 | 2,439 | 2,439 | 2,352 | 2,352 | -57 | -2.4% | 700 |
2020/08/05 | 2,436 | 2,436 | 2,389 | 2,409 | +1 | ±0% | 400 |
2020/08/04 | 2,380 | 2,417 | 2,379 | 2,408 | ±0 | ±0% | 2,200 |
2020/08/03 | 2,406 | 2,437 | 2,400 | 2,408 | -35 | -1.4% | 2,700 |
2020/07/31 | 2,483 | 2,484 | 2,441 | 2,443 | -36 | -1.5% | 2,100 |
2020/07/30 | 2,440 | 2,482 | 2,440 | 2,479 | +39 | +1.6% | 1,200 |
2020/07/29 | 2,430 | 2,485 | 2,430 | 2,440 | -88 | -3.5% | 3,400 |
2020/07/28 | 2,528 | 2,528 | 2,528 | 2,528 | -21 | -0.8% | 400 |
2020/07/27 | 2,570 | 2,570 | 2,529 | 2,549 | +29 | +1.2% | 4,500 |
2020/07/22 | 2,529 | 2,529 | 2,512 | 2,520 | -35 | -1.4% | 3,200 |
2020/07/21 | 2,569 | 2,569 | 2,519 | 2,555 | +36 | +1.4% | 900 |
2020/07/20 | 2,502 | 2,519 | 2,501 | 2,519 | -24 | -0.9% | 1,000 |
2020/07/17 | 2,530 | 2,579 | 2,529 | 2,543 | +54 | +2.2% | 1,000 |
2020/07/16 | 2,596 | 2,596 | 2,489 | 2,489 | -57 | -2.2% | 500 |
2020/07/15 | 2,450 | 2,546 | 2,450 | 2,546 | +141 | +5.9% | 1,000 |
2020/07/14 | 2,418 | 2,418 | 2,405 | 2,405 | -7 | -0.3% | 1,300 |
2020/07/13 | 2,393 | 2,428 | 2,392 | 2,412 | +2 | +0.1% | 2,000 |
2020/07/10 | 2,509 | 2,556 | 2,410 | 2,410 | -50 | -2% | 5,300 |
2020/07/09 | 2,470 | 2,488 | 2,460 | 2,460 | -19 | -0.8% | 6,100 |
2020/07/08 | 2,489 | 2,538 | 2,479 | 2,479 | -10 | -0.4% | 2,800 |
2020/07/07 | 2,456 | 2,647 | 2,456 | 2,489 | +35 | +1.4% | 5,000 |
2020/07/06 | 2,552 | 2,553 | 2,421 | 2,454 | -105 | -4.1% | 6,000 |
2020/07/03 | 2,512 | 2,559 | 2,512 | 2,559 | +40 | +1.6% | 1,400 |
2020/07/02 | 2,691 | 2,691 | 2,519 | 2,519 | -77 | -3% | 3,400 |
2020/07/01 | 2,618 | 2,630 | 2,596 | 2,596 | -50 | -1.9% | 1,600 |
2020/06/30 | 2,672 | 2,684 | 2,635 | 2,646 | -34 | -1.3% | 800 |
2020/06/29 | 2,676 | 2,680 | 2,654 | 2,680 | +54 | +2.1% | 3,700 |
2020/06/26 | 2,699 | 2,699 | 2,625 | 2,626 | -1 | ±0% | 3,000 |
2020/06/25 | 2,582 | 2,650 | 2,582 | 2,627 | -55 | -2.1% | 2,200 |
2020/06/24 | 2,677 | 2,682 | 2,677 | 2,682 | +55 | +2.1% | 500 |
2020/06/23 | 2,623 | 2,630 | 2,603 | 2,627 | -9 | -0.3% | 1,400 |
2020/06/22 | 2,688 | 2,688 | 2,626 | 2,636 | +39 | +1.5% | 3,300 |
2020/06/19 | 2,625 | 2,625 | 2,581 | 2,597 | +15 | +0.6% | 1,000 |
2020/06/18 | 2,624 | 2,624 | 2,574 | 2,582 | -9 | -0.3% | 1,100 |
2020/06/17 | 2,641 | 2,641 | 2,543 | 2,591 | -45 | -1.7% | 800 |
2020/06/16 | 2,687 | 2,687 | 2,608 | 2,636 | +49 | +1.9% | 2,600 |
2020/06/15 | 2,651 | 2,653 | 2,587 | 2,587 | -14 | -0.5% | 1,400 |
2020/06/12 | 2,501 | 2,655 | 2,500 | 2,601 | -27 | -1% | 4,600 |
2020/06/11 | 2,662 | 2,671 | 2,628 | 2,628 | -34 | -1.3% | 4,100 |
2020/06/10 | 2,699 | 2,699 | 2,661 | 2,662 | -23 | -0.9% | 1,900 |
2020/06/09 | 2,675 | 2,685 | 2,661 | 2,685 | +12 | +0.4% | 1,600 |
2020/06/08 | 2,671 | 2,697 | 2,671 | 2,673 | -15 | -0.6% | 2,100 |
2020/06/05 | 2,725 | 2,725 | 2,688 | 2,688 | -37 | -1.4% | 2,700 |
2020/06/04 | 2,740 | 2,750 | 2,711 | 2,725 | -15 | -0.5% | 2,400 |
2020/06/03 | 2,800 | 2,800 | 2,740 | 2,740 | -60 | -2.1% | 3,300 |
2020/06/02 | 2,752 | 2,800 | 2,726 | 2,800 | +48 | +1.7% | 5,700 |
2020/06/01 | 2,744 | 2,774 | 2,717 | 2,752 | +8 | +0.3% | 3,100 |
1051~
1100
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「日ケミファ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
日ケミファ | 151,100円 | +2.5% | - | 3.31% | 90.86倍 | 0.29倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
ティムス | 20,500円 | - | - | 0.00% | - | 2.78倍 |
|
東京農工大発創薬ベンチャー。黒カビ由来の急性期脳梗塞薬候補品を香港拠点ジーシンに導出 |
ノイルイミューン | 17,300円 | -97.8% | - | 0.00% | - | 1.50倍 |
|
独自技術用いたCAR-T細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
カルナバイオ | 31,000円 | -43.1% | - | 0.00% | - | 1.84倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
VIS | 89,000円 | +87.8% | +265.7% | 0.00% | 53.45倍 | 2.45倍 |
|
mRNA標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
市場注目の銘柄
チャート関連のコラム